Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Rapid Molecular Flu Testing Platforms Market Size Forecast: How Big Could The Market Get By 2030?
The rapid molecular flu testing platforms market size has seen substantial expansion in recent years. It is anticipated to increase from $2.71 billion in 2025 to $2.99 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.3%. The market’s historical growth can be attributed to factors like the rising prevalence of influenza, the demand for rapid diagnostic results, the adoption of rt-pcr technologies, the development of hospital and clinical testing infrastructure, and increasing awareness of infectious disease management.
The rapid molecular flu testing platforms market is projected for significant expansion over the next few years. It is predicted to reach $4.47 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 10.6%. This growth during the forecast period is attributable to factors such as the integration of AI and IoT for swift diagnostics, the proliferation of portable and point-of-care platforms, the creation of multiplex and high-throughput testing systems, increased investment in molecular diagnostic technologies, and the expansion of home-based and decentralized testing options. Key trends anticipated during this period encompass the widespread adoption of rapid point-of-care testing, advanced multiplex molecular diagnostics, seamless integration with laboratory information systems, automated sample processing capabilities, and the emergence of high-throughput testing platforms.
Get A Free Sample Report With In-Depth Market Insights:
Rapid Molecular Flu Testing Platforms Market Growth Factors Behind Sustained Expansion
The rising occurrence of seasonal and pandemic influenza outbreaks is projected to drive the expansion of the rapid molecular flu testing platforms market. These outbreaks are characterized by the recurrent or extensive spread of influenza infections, stemming from existing or new influenza viruses. The escalating frequency and severity of these outbreaks are fueled by elements like significant population movement, regular international journeys, dense urban populations, viral genetic changes, and inadequate vaccination rates, all contributing to swift virus transmission. Rapid molecular flu testing platforms are essential for handling seasonal and pandemic influenza outbreaks, as they facilitate quick and very precise identification of influenza viruses, aiding prompt clinical choices, early commencement of treatment, and robust infection prevention strategies. For example, data from February 2026, provided by the Centers for Disease Control and Prevention (CDC), a US-based government agency, indicated that during the 2025–2026 influenza season, influenza infections in the United States led to an estimated 290,000–450,000 hospitalizations and 34,000–53,000 deaths, highlighting the considerable public health and financial impact of the illness. Consequently, the rising global occurrence of seasonal and pandemic influenza outbreaks is propelling the expansion of the rapid molecular flu testing platforms market.
Rapid Molecular Flu Testing Platforms Market Segmentation And Category Overview
The rapid molecular flu testing platforms market covered in this report is segmented –
1) By Product Type: Benchtop Platforms, Portable Platforms, Other Product Types
2) By Sample Type: Nasopharyngeal Swabs, Throat Swabs, Saliva, Other Sample Types
3) By Technology: Reverse Transcription Polymerase Chain Reaction (RT-PCR), Isothermal Nucleic Acid Amplification, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Based, Other Technologies
4) By Distribution Channel: Direct Sales, Distributors, Online Sales, Other Distribution Channels
5) By End User: Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, Other End Users
Subsegments:
1) By Benchtop Platforms: Multiplex Testing Platform, High Throughput Platform, Automated Sample Processing Platform, Standard Laboratory Platform
2) By Portable Platforms: Handheld Testing Platform, Point Of Care Testing Platform, Battery Operated Portable Platform, Field Deployable Platform
3) By Other Product Types: Integrated Workflow Platform, Compact Diagnostic Platform, Rapid Screening Platform, Custom Configured Platform
Rapid Molecular Flu Testing Platforms Market Industry Trends Fueling Future Revenue Growth
Major companies within the rapid molecular flu testing platforms market are increasingly prioritizing the development of sophisticated multiplex molecular solutions, such as temperature-activated generation of signal (TAGS) technology. This focus aims to achieve high-throughput and concurrent detection of multiple respiratory pathogens, including influenza A and B, from a single patient sample. TAGS technology is an advanced PCR innovation that allows for the differentiation of various genetic targets within a singular fluorescence channel, making possible up to 15 diagnostic results in one test well. For example, in September 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based healthcare company, introduced the cobas Respiratory flex test. This test enables the swift identification of up to 12 respiratory viruses, including influenza A and B, when processed on Roche’s cobas 5800, 6800, and 8800 high-throughput molecular systems. Such a solution supports flexible, syndromic panel testing with high throughput, thereby streamlining laboratory workflows and resources while facilitating accurate and timely diagnosis of respiratory infections.
Rapid Molecular Flu Testing Platforms Market Top Companies Driving Competitive Growth
Major companies operating in the rapid molecular flu testing platforms market are Roche Diagnostics, Thermo Fisher Scientific, Abbott Laboratories, Siemens Healthineers, Becton Dickinson (BD), bioMérieux, Bio-Rad Laboratories, Qiagen N.V., Seegene Inc., BioPerfectus, Fapon Biotech, Visby Medical, Vircell S.L., QuantuMDx Group, Altona Diagnostics, Creative Diagnostics, Princeton BioMeditech Corporation, Credo Diagnostics, Genetic Signatures Ltd, AccuBioTech, Kogene Co. Ltd., Ameritek Inc., Alpha Diagnostic Intl, Medlere Ltd, ProtonDx Ltd.
View The Full Rapid Molecular Flu Testing Platforms Market Report:
Rapid Molecular Flu Testing Platforms Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the rapid molecular flu testing platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rapid molecular flu testing platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
